Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.
Selegiline orally disintegrating tablet is a potent, selective and irreversible inhibitor of monoamine oxidase type B. It is delivered in an innovative formulation that largely bypasses the gut and first-pass hepatic metabolism by allowing transbuccal absorption. Selegiline orally disintegrating tablet dissolves in the mouth within seconds and is rapidly absorbed directly into the systemic circulation, increasing parent drug bioavailability and lowering plasma metabolites compared with conventional oral formulations. Adding selegiline orally disintegrating tablet to levodopa in patients experiencing 'wearing-off' episodes significantly decreases off time and increases dyskinesia-free 'on' time. Adding selegiline orally disintegrating tablet to levodopa also significantly improves Unified Parkinson's Disease Rating Scale motor scores and patients' and physicians' ratings of disease severity. Selegiline orally disintegrating tablet has been demonstrated to be safe and well tolerated in placebo-controlled clinical trials.
Lew
Mark F
MF
Department of Neurology, University of Southern California, Keck School of Medicine, 1520 San Pablo St., HCC 2, Ste, 3000, Los Angeles, CA 90033, USA. marklew@usc.edu
D000284:Administration, Oral; D004305:Dose-Response Relationship, Drug; D005104:Expert Testimony; D006801:Humans; D015201:Meta-Analysis as Topic; D008996:Monoamine Oxidase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D004364:Pharmaceutical Preparations; D012642:Selegiline / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
D008996:Monoamine Oxidase Inhibitors; D004364:Pharmaceutical Preparations; D012642:Selegiline